
## Brigida Anna Maiorano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/202268/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?. Cancers, 2019, 11, 1055.	1.7	40
2	Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives. Cancers, 2021, 13, 4438.	1.7	40
3	Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma. Frontiers in Oncology, 2019, 9, 232.	1.3	31
4	Conjunctival Melanoma: Genetic and Epigenetic Insights of a Distinct Type of Melanoma. International Journal of Molecular Sciences, 2019, 20, 5447.	1.8	29
5	Efficacy of immune checkpoint inhibitors in different types of melanoma. Human Vaccines and Immunotherapeutics, 2021, 17, 4-13.	1.4	19
6	Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities. Vaccines, 2021, 9, 623.	2.1	17
7	Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis. Pharmaceuticals, 2021, 14, 476.	1.7	16
8	Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives. International Journal of Molecular Sciences, 2022, 23, 820.	1.8	15
9	The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy. International Journal of Molecular Sciences, 2022, 23, 3871.	1.8	14
10	Biomarkers of response to advanced prostate cancer therapy. Expert Review of Molecular Diagnostics, 2020, 20, 195-205.	1.5	12
11	Immunotherapy in advanced anal cancer: Is the beginning of a new era?. Cancer Treatment Reviews, 2022, 105, 102373.	3.4	12
12	Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day. Biomedicines, 2022, 10, 411.	1.4	11
13	Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic perspective. Seminars in Cancer Biology, 2022, 86, 997-1007.	4.3	8
14	Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions. Critical Reviews in Oncology/Hematology, 2019, 139, 83-86.	2.0	7
15	The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patients' Age: A Systematic Review and Meta-Analysis. Journal of Immunotherapy, 2020, 43, 95-103.	1.2	7
16	How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review. Frontiers in Oncology, 2022, 12, 844801.	1.3	7
17	Immune-checkpoint inhibitors in renal transplanted patients affected by melanoma: a systematic review. Immunotherapy, 2022, 14, 65-75.	1.0	6
18	Proteomics of Pancreatic Neuroendocrine Tumors: A Systematic Review. Protein and Peptide Letters, 2020, 27, 1276-1287.	0.4	2

#	Article	IF	CITATIONS
19	First Case of Mature Teratoma and Yolk Sac Testis Tumor Associated to Inherited MEN-1 Syndrome. Frontiers in Endocrinology, 2019, 10, 365.	1.5	1
20	Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience. Diagnostics, 2022, 12, 685.	1.3	1